

FINANCIAL TEAR SHEET

Corporate Profile

Adaptimmune is a leader in the TCR T-cell therapy space focused on developing novel cancer immunotherapy products. We utilize the body's own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets - whether intracellular or surface expressed - for administration to patients. We engineer TCRs to increase their affinity to cancer-specific peptides in order to target and potentially destroy cancer cells in patients.

Our wholly-owned pipeline of SPEAR T-cell therapies and targets continues to evolve; SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO are moving into and through clinical studies. In addition to the targets for which clinical and preclinical evaluation is ongoing, we continue to build a pipeline of proprietary TCR therapeutic candidates: We have identified over 25 intracellular target peptides preferentially expressed in cancer cells and are currently progressing 12 through unpartnered research programs. We believe these research programs are relevant to a wide range of cancer indications.

We believe our approach will lead to SPEAR therapeutic candidates that have the potential to significantly impact cancer treatment and the clinical outcomes of patients with cancer.

Primary IR Contact

Investor Contact

Email:


IR@adaptimmune.com

Stock Performance

ADAP (AMERICAN DEPOSITARY SHARES)

Exchange	NASDAQ GS (US Dollar)
Price	\$8.28
Change (%)	0.00 (0.00%)
Volume	243,597
52 Week Low	\$3.76
Market Cap	\$4,646,028,275
Rolling EPS	-1.00
PE Ratio	0
Shares Outstanding	561,114,526

Data as of 09/20/17 4:00 p.m. ET



Recent Headlines & Events

09/07/17

[GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO](#)

08/30/17

[Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker](#)

08/03/17

[Adaptimmune Reports Second Quarter 2017 Financial Results](#)

DATE	TITLE
09/25/17 9:15 a.m. ET	<u>Adaptimmune at Cell and Gene Therapy CEO Conference</u> Location Four Seasons Hotel Boston, MA
09/28/17 10:30 a.m. ET	<u>Adaptimmune at Leerink Partners Roundtable Series: Rare Disease and Immunology</u>

SEC Filings

Corporate Governance

FILING DATE	FORM	<u>James Noble</u>	Chief Executive Officer
09/11/17	<u>SC 13G</u>	<u>Adrian Rawcliffe</u>	Chief Financial Officer
09/07/17	<u>8-K</u>	<u>Helen Tayton-Martin, PhD, MBA</u>	Chief Operating Officer
08/03/17	<u>10-Q</u>	<u>Rafael Amado, MD</u>	Chief Medical Officer
08/03/17	<u>8-K</u>	<u>Bent Jakobsen, PhD</u>	Scientific Co-Founder
		<u>Gwendolyn Binder-Scholl, PhD</u>	Chief Technology Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.